Tonghua Dongbao Pharmaceutical Co.Ltd(600867) ( Tonghua Dongbao Pharmaceutical Co.Ltd(600867) ) announced on the evening of March 17 that the company plans to transfer Xiamen Amoytop Biotech Co.Ltd(688278) 20.5 million shares held by it to Guangzhou Houbao investment partnership (limited partnership), accounting for 5.04% of Xiamen Amoytop Biotech Co.Ltd(688278) current total share capital, with a transfer price of 20.16 yuan / share and a total transfer price of 413 million yuan. It is worth mentioning that this transfer is the second transfer of Tonghua Dongbao Pharmaceutical Co.Ltd(600867) since transferred some shares of Xiamen Amoytop Biotech Co.Ltd(688278) with an agreement of 460 million yuan in January this year. The two agreement transfers have brought a total cash flow of 873 million yuan to the company, which will significantly increase the company’s net profit and earnings per share in the first quarter.
Tonghua Dongbao Pharmaceutical Co.Ltd(600867) said that the company’s gradual transfer of Xiamen Amoytop Biotech Co.Ltd(688278) part of its shares is an overall arrangement made to realize the long-term development strategic plan. This will help the company to withdraw funds and improve the efficiency of asset use. On the one hand, more abundant capital reserves create more space for future investment in innovation and R & D and high-quality project cooperation, and help the company focus on the transformation and development of innovative pharmaceutical enterprises; On the other hand, the company will continue to increase cash dividends and timely repurchase shares according to market conditions to improve the interests of all shareholders of the company.
In recent years, Tonghua Dongbao Pharmaceutical Co.Ltd(600867) has continuously improved the innovation and R & D system, further established and improved relevant mechanisms, and comprehensively and systematically improved the innovation and R & D capability. In 2021, the company vertically and horizontally extended the layout of the sector, focusing on the innovative research and development of the diabetes field, and constantly enriching the pipeline for research and development of diabetes drugs.
In the longitudinal aspect, Tonghua Dongbao Pharmaceutical Co.Ltd(600867) continues to deepen the field of diabetes treatment, and has a comprehensive and forward-looking pipeline layout in the industry. The company’s multi-level product system covers long-acting, medium acting, quick acting and super quick acting insulin, basic + quick acting double insulin, GLP-1 receptor agonist, insulin + GLP-1 compound preparation and other products. In addition, the company’s R & D pipeline also includes three leading innovative drugs in the field of diabetes treatment, including the world’s first SGLT1/ SGLT2/ DPP4 three target inhibitor, GIP/ GLP dual target agonist and small molecule GLP-1 receptor agonist.
In terms of horizontal collaborative innovation, Tonghua Dongbao Pharmaceutical Co.Ltd(600867) strategy extends to the field of gout / hyperuricemia treatment, focusing on a kind of innovation. At present, two class I innovative drugs URAT1 inhibitors and a double target compound preparation are under development, of which the former has entered the stage of clinical trial. The company has been deeply engaged in the field of chronic disease treatment for a long time, and has profound accumulation in many aspects of the industry. The treatment field of gout / hyperuricemia is also the field of endocrine metabolism and has a broad market. The company aims to develop first in class and best in class products and realize coordinated and integrated development with existing business sectors.
In terms of opening up and cooperation with the outside world, Tonghua Dongbao Pharmaceutical Co.Ltd(600867) actively pays attention to high-quality projects and targets in the industry, and is not limited to using project cooperation, equity investment and other methods to promote epitaxial development. The withdrawal of funds this time will increase the scope of potential cooperation of the company in the future, improve the possibility of cooperation and expand the growth potential and space. The company will adhere to the parallel development strategy of “independent R & D + foreign cooperation”, use various ways to improve R & D efficiency, improve R & D system, extend layout scope and expand incremental space.
